Schizophrenia & Psychoses

FDA Approves Schizophrenia Medication With Digital Ingestion Sensor

FDA Approves Schizophrenia Medication With Digital Ingestion Sensor

By

The ability to track ingestion of medications prescribed for mental illness may be useful for some patients.

Diabetes Risk for Children, Young Adults on Second-Generation Antipsychotics

Diabetes Risk for Children, Young Adults on Second-Generation Antipsychotics

By

Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.

FDA Issues Refusal to File Letter in Response to New Schizophrenia Drug

FDA Issues Refusal to File Letter in Response to New Schizophrenia Drug

By

The FDA issued a refusal to file letter for a new drug application.

Guidance for Managing Treatment-Resistant Schizophrenia

Guidance for Managing Treatment-Resistant Schizophrenia

By

Different clinical and neurobiologic pathways may be involved in treatment-resistant schizophrenia as it is not a homogeneous subgroup within the schizophrenia spectrum.

Why Do Antipsychotics Cause Weight Gain?

Why Do Antipsychotics Cause Weight Gain?

Researchers from the University of Texas Southwestern Medical Center have discovered the cellular receptor that causes weight gain from antipsychotic drugs.

Shared Decision Making in Psychiatry:  An Effective Practice Strategy

Shared Decision Making in Psychiatry: An Effective Practice Strategy

By

Shared decision making encourages a clinical partnership that can result in optimal treatment outcomes.

Psychosis Relapse Risk With Continued Cannabis Use and Poor Medication Adherence

Psychosis Relapse Risk With Continued Cannabis Use and Poor Medication Adherence

By

Interventions targeted at improving medication adherence might mitigate adverse effects of cannabis use on psychosis outcomes.

Long-Acting Injectable Antipsychotic May Reduce Costs, Increase Adherence in Schizophrenia

Long-Acting Injectable Antipsychotic May Reduce Costs, Increase Adherence in Schizophrenia

By

Long-acting injectables should be considered earlier in the treatment of schizophrenia.

Increases in Autonomic Function May Predict Auditory Hallucinations in SCZ

Increases in Autonomic Function May Predict Auditory Hallucinations in SCZ

By

Increases in autonomic function may predict the occurrence and severity of auditory hallucinations in patients with schizophrenia, suggesting a regulation of these experiences by the autonomic nervous system.

Diabetes Mellitus More Prevalent In Psychiatric Patients Than General Population

Diabetes Mellitus More Prevalent In Psychiatric Patients Than General Population

By

Diabetes mellitus (DM) appears to be more prevalent in the psychiatric setting than in the general population.

Schizophrenia Relapse Rate Lower With Injectable Versus Oral Antipsychotics

Schizophrenia Relapse Rate Lower With Injectable Versus Oral Antipsychotics

By

The risk for rehospitalization was 22% lower during treatment with long-acting injectable antipsychotic medications compared with treatment with equivalent oral formulations in the total cohort.

Schizophrenia Symptoms May Benefit From Specific Kind of Talk Therapy

Schizophrenia Symptoms May Benefit From Specific Kind of Talk Therapy

Schizophrenia patients may benefit from a a specific type of talk therapy, according to a new study from the University of Pennsylvania.

Concomitant Use of Antidepressants, Antipsychotics Linked to T2D Risk

Concomitant Use of Antidepressants, Antipsychotics Linked to T2D Risk

By

Concomitant SSRI/SNRI use was associated with an increased diabetes risk in AAP-treated young people.

Schizophrenia: Are There Any Effective Pharmacologic Combinations?

Schizophrenia: Are There Any Effective Pharmacologic Combinations?

By

There is currently no approved drug combination for treatment-resistant schizophrenia.

Cardiometabolic Outcomes in Schizophrenia Improved by Liraglutide

Cardiometabolic Outcomes in Schizophrenia Improved by Liraglutide

By

In patients with schizophrenia being treated with clozapine or olanzapine, liraglutide significantly improved glucose tolerance, body weight, and other cardiometabolic disturbances.

Schizophrenia Treatment Can Benefit From Electroconvulsive Therapy

Schizophrenia Treatment Can Benefit From Electroconvulsive Therapy

By

Electroconvulsive therapy can be a clinically effective treatment for patients with severe forms of schizophrenia.

Valbenazine Effective for Tardive Dyskinesia in Schizophrenia

Valbenazine Effective for Tardive Dyskinesia in Schizophrenia

By

Long-term valbenazine may be beneficial in managing tardive dyskinesia.

BMI In Schizophrenia Patients Associated With C-reactive Protein

BMI In Schizophrenia Patients Associated With C-reactive Protein

By

Body mass index in patients with schizophrenia is linked to C-reactive protein.

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

Adolescents With Schizophrenia Prove Able to Tolerate Lurasidone

By

Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in adolescents.

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

Psychotropic Medication Heightens Risk of Hip Fracture, MOF

By

Mental disorders and psychotropic medication use are associated with an increased risk for fracture but are not fully captured by FRAX tool.

Antipsychotic Nonadherence Due to Social Stigma

Antipsychotic Nonadherence Due to Social Stigma

By

Schizophrenia was perceived as more distressful and with higher perceived social stigma than other disorders.

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

Schizophrenia Patients on Multiple Drugs Experience Cognitive Burden

By

Scientists researched the association between multiple drug treatments for psychotic disorders and anticholinergic burden.

Schizophrenia Risk Linked to Cannabis Use

Schizophrenia Risk Linked to Cannabis Use

By

Cannabis is the most widely misused illicit drug.

Schizophrenia Associated With Years of Life Lost

Schizophrenia Associated With Years of Life Lost

By

Schizophrenia was associated with 13 to 15 years of potential life lost.

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

Low Prenatal Weight Gain Linked to Offspring Psychosis Risk

By

The risk for offspring's development of psychosis is connected to maternal weight gain during pregnancy.

Antipsychotic Adherence Boosted by Financial Incentives

Antipsychotic Adherence Boosted by Financial Incentives

By

A trial at 3 mental health centers in The Netherlands revealed that patients with financial incentives have better compliance.

Schizophrenia Symptoms Reduced by Vitamin B

Adding high-dose B vitamins to traditional antipsychotic treatments reduces schizophrenia symptoms more than traditional treatments alone.

FDA Approves New Schizophrenia Treatment for Adolescents

FDA Approves New Schizophrenia Treatment for Adolescents

By

The FDA has approved a new treatment for adolescents between the ages of 13 and 17 years who are diagnosed with schizophrenia.

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

Factors Predicting Favorable Outcomes in First-Episode Psychosis Without Medication

By

Researchers profiled which young people may do well after first-episode psychosis without medication.

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

Low-Dose Metformin May Reduce Body Weight and BMI in Clozapine-Treated Schizophrenia

By

These study results indicate that early intervention with low doses of metformin in patients with few metabolic abnormalities may be beneficial.

Sign Up for Free e-newsletters